$94.1M in CY2024 Part D spend15K claims · 5K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Nemolizumab-Ilto used for?
NEMLUVIO is an interleukin-31 receptor antagonist indicated for: Prurigo Nodularis The treatment of adults with prurigo nodularis. ( 1.1 ) Atopic Dermatitis The treatment of adults and pediatric pa....
Is there a generic for Nemolizumab-Ilto?
No. Nemolizumab-Ilto is brand-only with no generic equivalents currently in market.
How much does my plan pay for Nemolizumab-Ilto?
NADAC pricing data not currently available for this drug.
Is Nemolizumab-Ilto on the FDA shortage list?
No. Nemolizumab-Ilto is not currently on the FDA Drug Shortage Database.
5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.